We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
Read MoreHide Full Article
Intellia Therapeutics, Inc. (NTLA - Free Report) announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for the treatment of hereditary angioedema (HAE).
The global double-blind, placebo-controlled study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The primary endpoint of the study is to see the change in number of HAE attacks from week five through week 28 of treatment.
Patient screening is currently ongoing in the study.
Year to date, shares of Intellia have plunged 41.5% compared with the industry’s decrease of 2.8%.
Image Source: Zacks Investment Research
More on NTLA's Gene-Editing Candidate NTLA-2002
NTLA-2002 is Intellia’s investigational single-dose CRISPR/Cas9 gene-editing therapy, which is being developed as a one-time cure for HAE. It is a rare genetic condition marked by severe inflammatory attacks in various body organs and tissues, which can be painful and even life-threatening.
Despite the current treatment options that require chronic administration for disease control, HAE attacks still occur. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity.
Previously, data from the ongoing phase I/II study showed that treatment with a single-dose of NTLA-2002 can lead to a complete response – no more attacks as well as no further treatment required.
In June, the company announced encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating HAE.
Studies on NTLA's Another Candidate NTLA-2001 Progressing Well
Intellia is collaborating with Regeneron Pharmaceuticals (REGN - Free Report) for the development of its investigational in vivo genome-editing candidate, NTLA-2001.
NTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for NTLA-2001, REGN shares 25% of the development costs and commercial profits.
NTLA-2001 is being studied for two indications, transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The ongoing phase III MAGNITUDE study is evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy. If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.
Intellia also plans to initiate a pivotal phase III study evaluating NTLA-2001 as a single-dose treatment in ATTRv-PN by 2024-end.
NTLA's Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
Intellia Therapeutics, Inc. (NTLA - Free Report) announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for the treatment of hereditary angioedema (HAE).
The global double-blind, placebo-controlled study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The primary endpoint of the study is to see the change in number of HAE attacks from week five through week 28 of treatment.
Patient screening is currently ongoing in the study.
Year to date, shares of Intellia have plunged 41.5% compared with the industry’s decrease of 2.8%.
Image Source: Zacks Investment Research
More on NTLA's Gene-Editing Candidate NTLA-2002
NTLA-2002 is Intellia’s investigational single-dose CRISPR/Cas9 gene-editing therapy, which is being developed as a one-time cure for HAE. It is a rare genetic condition marked by severe inflammatory attacks in various body organs and tissues, which can be painful and even life-threatening.
Despite the current treatment options that require chronic administration for disease control, HAE attacks still occur. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity.
Previously, data from the ongoing phase I/II study showed that treatment with a single-dose of NTLA-2002 can lead to a complete response – no more attacks as well as no further treatment required.
In June, the company announced encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating HAE.
Studies on NTLA's Another Candidate NTLA-2001 Progressing Well
Intellia is collaborating with Regeneron Pharmaceuticals (REGN - Free Report) for the development of its investigational in vivo genome-editing candidate, NTLA-2001.
NTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for NTLA-2001, REGN shares 25% of the development costs and commercial profits.
NTLA-2001 is being studied for two indications, transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The ongoing phase III MAGNITUDE study is evaluating NTLA-2001 to treat ATTR amyloidosis with cardiomyopathy. If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001.
Intellia also plans to initiate a pivotal phase III study evaluating NTLA-2001 as a single-dose treatment in ATTRv-PN by 2024-end.
NTLA's Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.